Patient‐reported receipt of and interest in smoking‐cessation interventions after a diagnosis of cancer
Mary E. Cooley(Dana-Farber Cancer Institute), Bruce E. Johnson(Beth Israel Deaconess Medical Center), Qian Wang(Central South University), Karen M. Emmons(Dana-Farber Cancer Institute), Raphael Bueno(Brigham and Women's Hospital), Marshall R. Posner(Icahn School of Medicine at Mount Sinai), Robert I. Haddad(Broad Institute)
Cited by 56
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k